Ozempic vs Mounjaro: Single GLP-1 vs Dual GIP/GLP-1 Incretin
Ozempic and Mounjaro are the two powerhouse subcutaneous medications revolutionizing glycemic management and weight loss. Ozempic utilizes semaglutide to mimic the natural GLP-1 hormone, slowing stomach digestion and signaling satiety to the brain. Mounjaro takes incretin science further by adding GIP receptor agonism alongside GLP-1, producing deeper appetite suppression and enhanced insulin sensitivity.
Feature-by-Feature Comparison
Ozempic
Mounjaro
| Feature / Capability | Ozempic | Mounjaro |
|---|---|---|
| Active Molecule | Semaglutide | Tirzepatide |
| Receptor Targeting | GLP-1 receptor agonist only | Dual GIP and GLP-1 receptor agonist |
| Average Weight Loss | 15% total body weight reduction | 20–22% total body weight reduction |
| Weekly Injections | 0.25mg, 0.5mg, 1mg, 2mg pens | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg pens |
| A1C Reduction Power | High (1.5–1.8% average drop) | Very High (2.0–2.4% average drop) |
| Pre-filled Pen Format | ||
| Starting Price | $180.00 – $420.00 | $210.00 – $480.00 |
| View Ozempic | View Mounjaro |
The Final Verdict
Mounjaro targets both GIP and GLP-1 metabolic pathways, resulting in slightly higher average weight loss and glycemic control in clinical head-to-head trials. Ozempic (Semaglutide) is the world-renowned pioneer with the most extensive long-term cardiovascular safety data.
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. The accuracy of pricing and features may change over time. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.
Last updated: September 2026